US10512670B2 - Pharmaceutical composition for preventing or treating hair loss comprising chemokine (C-X-C motif) ligand 1 (CXCL1) protein or CXCL1 protein and minoxidil as active ingredient - Google Patents
Pharmaceutical composition for preventing or treating hair loss comprising chemokine (C-X-C motif) ligand 1 (CXCL1) protein or CXCL1 protein and minoxidil as active ingredient Download PDFInfo
- Publication number
- US10512670B2 US10512670B2 US16/014,812 US201816014812A US10512670B2 US 10512670 B2 US10512670 B2 US 10512670B2 US 201816014812 A US201816014812 A US 201816014812A US 10512670 B2 US10512670 B2 US 10512670B2
- Authority
- US
- United States
- Prior art keywords
- hair
- protein
- cxcl1
- minoxidil
- hair loss
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 75
- 208000024963 hair loss Diseases 0.000 title claims abstract description 69
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 title claims abstract description 66
- 229960003632 minoxidil Drugs 0.000 title claims abstract description 64
- 230000003676 hair loss Effects 0.000 title claims abstract description 59
- 239000004480 active ingredient Substances 0.000 title claims abstract description 31
- 102000016950 Chemokine CXCL1 Human genes 0.000 title claims description 137
- 108010014419 Chemokine CXCL1 Proteins 0.000 title claims description 137
- 108090000623 proteins and genes Proteins 0.000 title claims description 33
- 102000004169 proteins and genes Human genes 0.000 title claims description 32
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 22
- 210000004209 hair Anatomy 0.000 claims abstract description 124
- 239000000203 mixture Substances 0.000 claims abstract description 94
- 230000001737 promoting effect Effects 0.000 claims abstract description 32
- 230000003779 hair growth Effects 0.000 claims abstract description 30
- 239000002537 cosmetic Substances 0.000 claims abstract description 14
- 238000009472 formulation Methods 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 22
- 235000013305 food Nutrition 0.000 claims description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 13
- 230000003645 female-pattern hair loss Effects 0.000 claims description 3
- 230000003273 male-pattern hair loss Effects 0.000 claims description 3
- 239000013583 drug formulation Substances 0.000 claims description 2
- 230000000284 resting effect Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 51
- 239000003814 drug Substances 0.000 abstract description 28
- 229940079593 drug Drugs 0.000 abstract description 25
- 230000003752 improving hair Effects 0.000 abstract description 13
- 230000036541 health Effects 0.000 abstract description 9
- 235000013376 functional food Nutrition 0.000 abstract description 5
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 abstract description 4
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 3
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 229940127557 pharmaceutical product Drugs 0.000 abstract description 2
- 102100034221 Growth-regulated alpha protein Human genes 0.000 abstract 3
- 235000018102 proteins Nutrition 0.000 description 30
- -1 aromatic amino acids Chemical class 0.000 description 29
- 239000003795 chemical substances by application Substances 0.000 description 25
- 239000004615 ingredient Substances 0.000 description 23
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 15
- 235000014113 dietary fatty acids Nutrition 0.000 description 14
- 239000000194 fatty acid Substances 0.000 description 14
- 229930195729 fatty acid Natural products 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 13
- 235000013361 beverage Nutrition 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 235000011187 glycerol Nutrition 0.000 description 10
- 239000003755 preservative agent Substances 0.000 description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 235000013336 milk Nutrition 0.000 description 8
- 210000004080 milk Anatomy 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000002453 shampoo Substances 0.000 description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 8
- 239000000443 aerosol Substances 0.000 description 7
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 7
- 239000008267 milk Substances 0.000 description 7
- 235000012149 noodles Nutrition 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 210000003128 head Anatomy 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000002562 thickening agent Substances 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 5
- 229960003237 betaine Drugs 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 210000003780 hair follicle Anatomy 0.000 description 5
- 229940057995 liquid paraffin Drugs 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 208000004631 alopecia areata Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000000720 eyelash Anatomy 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 238000007429 general method Methods 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000003002 pH adjusting agent Substances 0.000 description 4
- 235000019271 petrolatum Nutrition 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 229940032094 squalane Drugs 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 208000003024 Diffuse alopecia Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 231100000360 alopecia Toxicity 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 210000004709 eyebrow Anatomy 0.000 description 3
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 3
- 229960004039 finasteride Drugs 0.000 description 3
- 210000001061 forehead Anatomy 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000015243 ice cream Nutrition 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000006193 liquid solution Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 229940079520 minoxidil 10 mg Drugs 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000003658 preventing hair loss Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 201000001297 telogen effluvium Diseases 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl tetradecanoate Chemical group CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical class [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 235000015155 buttermilk Nutrition 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000014171 carbonated beverage Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 2
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 2
- 229960003338 crotamiton Drugs 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 230000002951 depilatory effect Effects 0.000 description 2
- 229940031578 diisopropyl adipate Drugs 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940100463 hexyl laurate Drugs 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000013622 meat product Nutrition 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 239000001508 potassium citrate Substances 0.000 description 2
- 229960002635 potassium citrate Drugs 0.000 description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 2
- 235000011082 potassium citrates Nutrition 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 150000003611 tocopherol derivatives Chemical class 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 239000004034 viscosity adjusting agent Substances 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- LVOGXJMCDAOKSQ-UHFFFAOYSA-N 10-oxo-10-propan-2-yloxydecanoic acid Chemical compound CC(C)OC(=O)CCCCCCCCC(O)=O LVOGXJMCDAOKSQ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 description 1
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- LIFHMKCDDVTICL-UHFFFAOYSA-N 6-(chloromethyl)phenanthridine Chemical compound C1=CC=C2C(CCl)=NC3=CC=CC=C3C2=C1 LIFHMKCDDVTICL-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- BTBJBAZGXNKLQC-UHFFFAOYSA-N ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 description 1
- 229940063953 ammonium lauryl sulfate Drugs 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000008133 cognitive development Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000010610 frozen noodles Nutrition 0.000 description 1
- 235000021456 frozen pasta Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229940100608 glycol distearate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003803 hair density Effects 0.000 description 1
- 230000003660 hair regeneration Effects 0.000 description 1
- 239000008266 hair spray Substances 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000055297 human CXCL1 Human genes 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000015094 jam Nutrition 0.000 description 1
- 235000008960 ketchup Nutrition 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 229940031957 lauric acid diethanolamide Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 235000020121 low-fat milk Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- OGGIFKYAUCDPFX-UHFFFAOYSA-N n,n-diethyldodecan-1-amine oxide Chemical compound CCCCCCCCCCCC[N+]([O-])(CC)CC OGGIFKYAUCDPFX-UHFFFAOYSA-N 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229940027779 persimmon extract Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000014059 processed cheese Nutrition 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940107889 rogaine Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/66—Proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present application discloses a composition for preventing, treating or improving hair loss, which comprises a CXCL1 (chemokine (C-X-C motif) ligand 1) protein, or a CXCL 1 protein and minoxidil as an active ingredient, and a composition for promoting hair generation or hair growth.
- CXCL1 chemokine (C-X-C motif) ligand 1
- CXCL 1 chemokine (C-X-C motif) ligand 1 protein
- minoxidil as an active ingredient
- Hair loss means a state without hair in a region where hair normally exists, and means that generally, the grown hair (coarse black hair) of the scalp is lost.
- the grown hair is lost unlike soft hair having no color and a thin thickness to cause a cosmetic problem.
- Koreans with lower hair density than Westerners there are between 50,000 and 70,000 hair and about 50 to 70 hair are normally lost per day. Accordingly, if the number of hair lost when you sleep or clean your hair exceeds 100, hair loss may be ongoing.
- the causes of hair loss are diverse, and genetic causes and androgen as a male hormone are considered to be important factors in the development of baldness. It is presumed that the female pattern hair loss occurs in the same way as male pattern hair loss, but there is a difference in clinical appearance. Alopecia areata is considered to be an autoimmune disease. Telogen effluvium is temporary hair loss caused by severe physical and mental stresses such as endocrine diseases, malnutrition, drug use, birth, fever, and surgery and caused by a part of the hair which does not fill the growth period and falls into the dormant state.
- hair loss is in progression of hair from a person who has a family history of baldness from the twenties or thirties.
- the border between forehead and head is pushed backward, and the forehead spreads in M-shape on both sides of the head, and hair loss gradually progresses to the head parietal region.
- the female hair loss is characterized by thinning the hair in the center of the head while the hair line on the forehead is maintained as compared with the male hair loss.
- alopecia areata is characteristic in the appearance of circular or oval depilatories with various sizes (hair is lost and looks like dots).
- Alopecia areata occurs mainly in the head, and rarely, occurs in beard, eyebrows and eyelashes, and a large depilatory is formed while enlarging the symptom area. If the entire hair falls off, it will be classified into all-hair alopecia (frontal hair alopecia) and whole-hair alopecia if the whole hair is lost.
- telogen effluvium is caused by entirely reducing the hair from 2 to 4 months after the cause stimulus occurs, and when the cause stimulus is removed, hair loss is reduced as the dormant hair returns to normal over several months.
- Minoxidil and Finasteride are representative drugs used to promote hair growth.
- Minoxidil of Upjohn Corporation in the US can cause side effects such as edema, arrhythmia and hairiness in long-term application, and the effect of minoxidil is most effective from 6 months to 1 year after use, and thereafter, it is known that the effect is slowly reduced.
- finasteride developed by Merck Corporation is known as a material which inhibits the activity of 5- ⁇ -reductase as an enzyme that acts on the male hormone testosterone metabolism in hair follicles, but it is reported that sexual dysfunction, depression and suicidal impulses are increased.
- the inventors made efforts to develop materials capable of preventing hair loss and promoting hair generation without side effects and thus verified that the CXCL1 protein in the body had an effect of promoting hair growth and completed the present disclosure.
- the present disclosure has been made in an effort to provide a pharmaceutical composition for preventing or treating hair loss comprising a chemokine (C-X-C motif) ligand 1 (CXCL1) protein; or a CXCL1 protein and minoxidil as an active ingredient.
- a chemokine (C-X-C motif) ligand 1 (CXCL1) protein or a CXCL1 protein and minoxidil as an active ingredient.
- the present disclosure has been also made in an effort to provide a quasi-drug composition, a cosmetic composition and a food composition for preventing or improving hair loss comprising a CXCL1 (chemokine (C-X-C motif) ligand 1) protein; or a CXCL1 protein and minoxidil as an active ingredient.
- CXCL1 chemokine (C-X-C motif) ligand 1
- the present disclosure has been also made in an effort to provide a pharmaceutical composition, a quasi-drug composition, a cosmetic composition and a food composition for promoting or stimulating hair generation or hair growth comprising a CXCL1(chemokine (C-X-C motif) ligand 1) protein; or a CXCL1 protein and minoxidil as an active ingredient.
- a pharmaceutical composition for promoting or stimulating hair generation or hair growth comprising a CXCL1(chemokine (C-X-C motif) ligand 1) protein; or a CXCL1 protein and minoxidil as an active ingredient.
- the present disclosure has been also made in an effort to provide a complex formulation for preventing or treating hair loss comprising a CXCL1(chemokine (C-X-C motif) ligand 1) protein; or a CXCL1 protein and minoxidil.
- An exemplary embodiment of the present disclosure provides a pharmaceutical composition for preventing or treating hair loss comprising a CXCL1 (chemokine (C-X-C motif) ligand 1) protein; or a CXCL1 protein and minoxidil as an active ingredient.
- CXCL1 chemokine (C-X-C motif) ligand 1
- a quasi-drug composition for preventing or improving hair loss comprising a CXCL1 (chemokine (C-X-C motif) ligand 1) protein; or a CXCL1 protein and minoxidil as an active ingredient.
- CXCL1 chemokine (C-X-C motif) ligand 1
- yet another exemplary embodiment of the present disclosure provides a cosmetic composition for preventing or improving hair loss comprising a CXCL1 (chemokine (C-X-C motif) ligand 1) protein; or a CXCL1 protein and minoxidil as an active ingredient.
- CXCL1 chemokine (C-X-C motif) ligand 1
- Still another exemplary embodiment of the present disclosure provides a food composition for preventing or improving hair loss comprising a CXCL1(chemokine (C-X-C motif) ligand 1) protein; or a CXCL1 protein and minoxidil as an active ingredient.
- a food composition for preventing or improving hair loss comprising a CXCL1(chemokine (C-X-C motif) ligand 1) protein; or a CXCL1 protein and minoxidil as an active ingredient.
- Still yet another exemplary embodiment of the present disclosure provides a pharmaceutical composition for promoting hair generation or hair growth comprising a CXCL1 (chemokine (C-X-C motif) ligand 1) protein; or a CXCL1 protein and minoxidil as an active ingredient.
- CXCL1 chemokine (C-X-C motif) ligand 1
- Still yet another exemplary embodiment of the present disclosure provides a quasi-drug composition for promoting hair generation or hair growth comprising a CXCL1 (chemokine (C-X-C motif) ligand 1) protein; or a CXCL1 protein and minoxidil as an active ingredient.
- CXCL1 chemokine (C-X-C motif) ligand 1
- Still yet another exemplary embodiment of the present disclosure provides a cosmetic composition for promoting hair generation or hair growth comprising a CXCL1 (chemokine (C-X-C motif) ligand 1) protein; or a CXCL1 protein and minoxidil as an active ingredient.
- a CXCL1 chemokine (C-X-C motif) ligand 1
- CXCL1 chemokine (C-X-C motif) ligand 1
- Still yet another exemplary embodiment of the present disclosure provides a food composition for promoting hair generation or hair growth comprising a CXCL1(chemokine (C-X-C motif) ligand 1) protein; or a CXCL1 protein and minoxidil as an active ingredient.
- a food composition for promoting hair generation or hair growth comprising a CXCL1(chemokine (C-X-C motif) ligand 1) protein; or a CXCL1 protein and minoxidil as an active ingredient.
- Still yet another exemplary embodiment of the present disclosure provides a complex formulation for preventing or treating hair loss comprising a CXCL1 (chemokine (C-X-C motif) ligand 1) protein and minoxidil.
- CXCL1 chemokine (C-X-C motif) ligand 1
- the composition for preventing hair loss or promoting hair generation comprising the CXCL1 protein, or the CXCL1 protein and the minoxidil as an active ingredient according to the present disclosure has no side effects at the time of treating hair loss and an excellent hair generation effect even in a short time and thus can be used as pharmaceutical products and usefully used as quasi-drugs, cosmetics and health functional foods.
- FIG. 1 is a diagram illustrating a result of measuring cell proliferation for 40 hrs after a CXCL1 protein is treated to DPC.
- FIG. 2 is a diagram illustrating a photograph of the back of a mouse after 15 days after hair of the back of a C3H/HeN mouse is removed using a hair removal agent and the CXCL1 protein is subcutaneously injected.
- FIG. 3 is a diagram illustrating a result of measuring an increased hair weight (mg) of the mouse after 15 days after hair of the back of a C3H/HeN mouse is removed using a hair removal agent and the CXCL1 protein is subcutaneously injected.
- FIG. 4 is a diagram illustrating a photograph of the back of a mouse after 14 days after hair of the back of a C3H/HeN mouse is removed using a hair removal agent and PBS, minoxidil, and the minoxidil and the CXCL1 protein are applied.
- FIG. 5 is a diagram illustrating a result of measuring an increased hair weight (mg) of the mouse after 14 days after hair of the back of a C3H/HeN mouse is removed using a hair removal agent and PBS, minoxidil, and the minoxidil and the CXCL1 protein are applied.
- the present disclosure provides a pharmaceutical composition for preventing or treating hair loss and a pharmaceutical composition for promoting hair generation or hair growth, comprising a CXCL1 protein as an active ingredient.
- Chemokine (C-X-C motif) ligand 1 is a kind of chemokine belonging to a CXC family
- Chemokine is a basic heparin-binding low-molecular protein for leukocytes migration and activation.
- the CXCL1 protein is secreted by human melanoma cells and has a mitosis promoting property and is involved the cause of melanoma.
- the CXCL1 protein is expressed in macrophages, neutrophils and epithelial cells and has a neutrophil activation function.
- the CXCL1 protein exhibits the effect by signaling through a chemokine receptor CXCR2 and is involved in inflammatory response, wound healing, and tumorigenesis.
- the CXCL1 protein may be configured by all or some peptides having an effect of preventing or treating hair loss and promoting hair generation or hair growth, and may be preferably configured by an amino acid sequence of SEQ ID NO:1, and functional equivalents and variants of the protein thereof.
- the functional equivalent of the protein includes proteins and polypeptides without entirely changing the activity of the protein molecule and proteins having functionally the same action are included in the scope of the present disclosure.
- the variant means for example, deletion, substitution, or addition of one or several amino acids in the amino acid sequence and has identify of 95% or more, preferably 98% or more, and more preferably 99% or more with the amino acid sequence.
- the “identity” means a ratio (%) of the number of the same amino acid residues in the other amino acid sequence to all amino acid residues of one amino acid sequence including the number of gaps, when a gap is introduced to two amino acid sequences or the two amino acid sequences are aligned to have the highest coherency without introducing the gap.
- “several” means an integer of 2 to 10, for example, 2 to 7, 2 to 5, 2 to 4, and 2 to 3.
- Particular examples of natural variants may include variants, splice variants, or the like based on polymorphisms such as SNP (monospecific polymorphism).
- the substitution is preferably conservative amino acid substitution.
- the conservative amino acid substitution may have a substantially equal structure or property to human CXCL1 having the amino acid sequence.
- nonpolar amino acids glycine, alanine, phenylalanine, valine, leucine, isoleucine, methionine, proline and tryptophan
- polar amino acids amino acids other than nonpolar amino acids
- charged amino acids acidic amino acids (aspartic acid and glutamic acid) and basic amino acids (arginine, histidine, and lysine
- non-charged amino acids amino acids other than charged amino acids
- aromatic amino acids phenylalanine, tryptophan, and tyrosine
- branched amino acids leucine, isoleucine, and valine
- aliphatic amino acids glycine, alanine, leucine, isoleucine, and valine
- a gene coding the CXCL1 protein may be constituted by a base sequence of SEQ ID NO:2, and the variants which may have functionally the same function as the nucleotide are included in the scope of the present disclosure.
- the variants which may have functionally the same function have sequence homology of at least 70% or more, preferably 80% or more, more preferably 90% or more, and much more preferably 95% or more with the base sequence represented by SEQ ID NO:2 as a result of addition, substitution or deletion of the base and mean a base sequence which may code a protein having substantially the same physiological activity as the protein coded by the base sequence represented by SEQ ID NO:2.
- some base sequences are modified by deletion, substitution or insertion, but include variants which may have functionally the same action as a nucleic acid molecule coding the CXCL1 protein.
- hair loss used in this specification may belong to cases where the number of hair is smaller than the general number beyond a normal hair level without a particular limitation, and preferably, any one or more selected from the group consisting of male pattern hair loss, female pattern hair loss, round hair loss and resting hair loss may correspond to hair loss which is treated or prevented by the composition according to the present disclosure. Further, the composition according to the present disclosure has an excellent effect of preventing hair loss before hair loss starts.
- hair generation used in this specification means that hair is generated and “hair growth” means that hair grows.
- An effect of the composition according to the present disclosure also includes an effect of promoting hair generation or hair growth.
- preventing used in this specification means all activities which suppress or delay hair loss by administering the composition of the present disclosure and the “treating” means all activities which improve or beneficially change symptoms associated with hair loss by the composition of the present disclosure.
- the pharmaceutical composition of the present disclosure may further include a carrier, an excipient, and a diluent which are properly and generally used in preparation of the pharmaceutical composition.
- the pharmaceutical composition of the present disclosure may be formulated and used in the form of an oral formulation such as a powder, a granule, a tablet, a capsule, a suspension, an emulsion, syrup, or an aerosol, an external preparation, a suppository, or a sterile injection solution according to a general method. It is preferred that a suitable formulation which is known in the art uses a formulation disclosed in the document.
- the carrier, the excipient, and the diluent which may be included in the pharmaceutical composition may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, or mineral oil.
- the formulation may be prepared by using a diluent or an excipient, such as a filler, an extender, a binder, a wetting agent, a disintegrating agent, and a surfactant which are generally used.
- a solid formulation for oral administration may include a tablet, a pill, a powder, a granule, a capsule, or the like, and the solid formulation may be prepared by mixing at least one excipient, for example, starch, calcium carbonate, sucrose, lactose, gelatin, and the like with the active ingredient.
- lubricants such as magnesium stearate and talc may be used in addition to simple excipients.
- a liquid formulation for oral administration may use a suspension, a solution, an emulsion, a syrup, and the like, and may include various excipients, for example, a wetting agent, a sweetener, an aromatic agent, a preserving agent, and the like in addition to water and liquid paraffin which are commonly used simple diluents.
- a formulation for parenteral administration may include a sterile aqueous solution, a non-aqueous solution, a suspension, an emulsion, and a lyophilizing agent, and a suppository.
- propylene glycol polyethylene glycol
- vegetable oils such as olive oil
- injectable ester such as ethyl oleate, and the like
- witepsol macrogol, Tween® 61, cacao butter, laurin, glycerogelatin, and the like
- witepsol macrogol, Tween® 61, cacao butter, laurin, glycerogelatin, and the like
- composition of the present disclosure may be administered with a pharmaceutically effective dose.
- the term “pharmaceutically effective dose” means an amount which is sufficient to treat the condition at a reasonable benefit/risk ratio applicable to medical treatment, and an effective dose level may be determined according to elements including a kind of disease of the patient, the severity, age of the patient, sex of the patient, activity of a drug, sensitivity to a drug, a time of administration, a pathway of administration, and an emission rate, duration of treatment, and simultaneously used drugs and other elements well-known in the medical field.
- the composition of the present disclosure may be administered as an individual therapeutic agent or administered in combination with other therapeutic agents, and sequentially or simultaneously administered with therapeutic agents in the related art. In addition, the composition of the present disclosure may be administered in single or multiple.
- a preferable dose of the composition of the present disclosure varies according to a condition and a weight of a patient, the degree of disease, a type of drug, a route and a period of administration, and a suitable total usage amount per day may be determined by a doctor within a correct medical judgment, but the composition may be administered with an amount of 0.001 to 1000 mg/kg, preferably 0.05 to 200 mg/kg, and more preferably 0.1 to 100 mg/kg one to several times per day.
- the subject is not particularly limited if the subject is a subject for preventing or treating the hair loss and any subject can be applied.
- any subject such as non-human animals such as a monkey, a dog, a cat, a rabbit, a guinea pig, a rat, a mouse, a cow, a sheep, a pig, and a goat and the human may be applied, but is not limited thereto.
- the administration method of the pharmaceutical composition according to the present disclosure is not particularly limited, and the pharmaceutical composition may be parenterally, orally, or topically administered, and preferably parenterally administered.
- the pharmaceutical composition may be injected or infused intradermally, subcutaneously, intramuscularly, intravenously, intramedullary, intraarticularly, intra-synovially, intrathecally, intraspinally, preferably subcutaneously and transdermally, or administered in an applying form which is applied to a region of hair loss or applied to a region where the progress of hair loss is predicted.
- the administration method is not particularly limited, and thus the pharmaceutical composition may be directly injected to the region where the progress of hair loss is predicted in an injection form.
- the administration method is not particularly limited, and thus the pharmaceutical composition may be injected to artery, vein, or the like. The most preferable administration of the composition of the present disclosure may be performed through subcutaneous injection or skin application.
- the administration level selected from the composition follows activity of the active ingredient, a route of administration, severity of the hair loss to be treated, a condition of the hair loss to be treated, and a previous history. However, from an amount of the active ingredient lower than an amount required for achieving a desired therapeutic effect, until a desired effect is achieved, slowly increasing a dose is within the knowledge in the art and a preferable dose may be determined according to an age, a gender, a body type, and a weight.
- the composition may be additionally processed before being prepared as a pharmaceutically acceptable formulation and preferably, may be ground or polished into smaller particles. Further, the composition varies according to a condition of a patient and a patient to be treated.
- composition of the present disclosure may be a formulation which may be administered by a method of directly being applied or dispersed on a skin, for example, hair or scalp, for example, a formulation such as cream, lotion, ointment, aerosol, shampoo, gel, or pack.
- a method for a mixed ingredient or agent suitable for each formulation is known in the art. When these agents are prepare by those skilled in the art, various mixed ingredients used for preparing general external preparation may be properly selected and used.
- the hair applied with the composition of the present disclosure includes all regions with hair roots and hair follicles throughout the body such as hair roots and hair follicles of the head, eyelashes and eyebrows, beards, armpits, and pubic hair.
- the present disclosure provides a pharmaceutical composition for preventing or treating hair loss, comprising a CXCL1 protein and minoxidil. Further, the present disclosure provides a pharmaceutical composition for promoting hair generation or hair growth, comprising a CXCL1 protein and minoxidil.
- the minoxidil is a hair generation agent for preventing or treating hair loss and a drug that exhibits a hair generation effect by increasing the blood flow in the hair follicle a great effect.
- a significantly excellent effect of preventing or treating the hair loss may be exhibited as compared with the effect of preventing or treating the hair loss which is verified in the case where the minoxidil is administered alone.
- the CXCL1 protein and the minoxidil of the present disclosure may be mixed and used with a weight ratio of 1:1 to 1:20, respectively, preferably 1:1 to 1:15, and more preferably 1:1 to 1:10.
- a composition in which the CXCL1 protein and the minoxidil are mixed with 1 ⁇ g/ml and 10 ⁇ g/ml is provided.
- the present disclosure provides a quasi-drug composition for preventing or improving hair loss comprising a CXCL1 protein as an active ingredient.
- the quasi-drug composition may be a quasi-drug composition for preventing or improving hair loss further comprising minoxidil.
- the present disclosure provides a quasi-drug composition for promoting hair generation or hair growth, comprising a CXCL1 protein; or a CXCL1 protein and minoxidil as an active ingredient.
- quadsi-drug product in the present disclosure means an article except for a device, a machine, or an apparatus which is used for the purpose of diagnosing, treating, alleviating, handling or preventing a disease of a person or an animal and a product except for a device, a machine, or an apparatus which is used for the purpose of having a pharmacological effect on the structure or function of a person or animal, as an article corresponding to one of fibers, rubber products, or similar products thereof used for the purpose of treating, alleviating, handling or preventing diseases of human or animals, articles except for devices or machines and similar products with weakly acting on the human body or without acting directly on the human body, and formulations for sterilization, insecticidal and similar uses for the prevention of infection, and includes skin external and personal hygiene products.
- the composition of the present disclosure may be used as it is or may be used together with other quasi-drug ingredients and may be properly used according to a general method.
- a mixed amount of active ingredients may be suitably determined according to a use purpose.
- the quasi-drug of the present disclosure is not particularly limited thereto, but may be prepared and used in a form of for example, creams, lotions, aerosols, shampoos, gels or packs.
- base materials such as white petrolatum, yellow petrolatum, lanolin, bleached beeswax, cetanol, stearyl alcohol, stearic acid, hydrogenated oil, gelling hydrocarbon, polyethylene glycol, liquid paraffin, and squalane; solvents and dissolution aids such as oleic acid, myristic acid isopropyl, triisooctanoic acid glycerin, crotamiton, diethyl sebacate, diisopropyl adipate, hexyl laurate, fatty acid, fatty acid ester, aliphatic alcohol and vegetable oil; antioxidants such as tocopherol derivatives, L-ascorbic acid, dibutylhydroxytoluene, and butylhydroxyanisole; preservatives such as parahydroxybenzoic acid ester; humectants such as glycerin, prop
- base materials such as white petrolatum, yellow petrolatum, lanolin, bleached beeswax, cetanol, stearyl alcohol, stearic acid, hydrogenated oil, gelling hydrocarbon, polyethylene glycol, liquid paraffin, and squalane; solvents and dissolution aids such as oleic acid, myristic acid isopropyl, diisopropyl adipate, isopropyl sebacate, triisooctanoic acid glycerin, crotamiton, diethyl sebacate, hexyl laurate, fatty acid, fatty acid ester, aliphatic alcohol and vegetable oil; antioxidants such as tocopherol derivatives, L-ascorbic acid, dibutylhydroxytoluene, and butylhydroxyanisole; preservatives such as parahydroxybenzoic acid ester; humectants such as glycerin, propylene glycol and
- stabilizers may be mixed.
- preservatives may be mixed.
- absorption promoters may be mixed.
- pH adjusters may be mixed.
- the present disclosure provides a cosmetic composition for preventing or improving hair loss and a cosmetic composition for promoting hair generation or hair growth, comprising a CXCL1 protein; or a CXCL1 protein and minoxidil as an active ingredient.
- the cosmetic composition may be a formulation of a hair tonic, a hair cream, a hair lotion, a hair shampoo, a hair rinse, a hair conditioner, a hair spray, a hair aerosol, pomade, a powder gel, a hair pack, a hair treatment, an eyebrow hair growth agent, an eyelash hair growth agent, and an eyelash nutrient as a skin quasi-drug formulation, but is not limited thereto.
- composition for preventing or improving hair loss and promoting hair generation or hair growth of the present disclosure may be used for pets by changing the formulation.
- the composition may be prepared in various forms such as solution, sol gel, emulsion, oil, wax, aerosol, and prepared by adding a neutral detergent with less irritation to the pet skin and excellent moisture retention.
- the cosmetic composition of the present disclosure may include generally acceptable ingredients in addition to the active ingredient without limitation and for example, may include general additives such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors, and carriers.
- any one or more of a synthetic surfactant which is a cleaning ingredient, a preservative, a thickener, a viscosity regulator, a pH adjusting agent, a perfume, a dye, a hair conditioning agent, and water may be included.
- a synthetic anionic surfactant of the synthetic surfactants is alkyl and alkyl ether sulfates, and as a representative example, sodium lauryl sulfate, ammonium lauryl sulfate, triethanolamine lauryl sulfate, sodium polyoxyethylene lauryl sulfate, ammonium polyoxyethylene lauryl sulfate, or the like is included.
- a synthetic amphoteric surfactant of the synthetic surfactants is alkyl betamine and alkylamidopropyl betaine, and as a representative example, cocodimethyl carboxymethyl betaine, lauryl dimethyl carboxymethyl betaine, lauryl dimethyl alpha-carboxyethyl betaine, cetyl dimethyl carboxymethyl betaine, cocamidopropyl betaine, or the like is included.
- the nonionic surfactant is alkanolamide and amine oxide, and lauryl diethylamine oxide, coconut oil alkyldimethylamine oxide, lauric acid diethanolamide, palm oil fatty acid diethanolamide, palm oil fatty acid monoethanolamide, or the like is included.
- any ingredient used in the present disclosure is widely known to the expert in the art as any general ingredient for maintaining basic property and quality as the shampoo.
- a pearlescent adjuvant As any ingredient, a pearlescent adjuvant, a preservative, a thickener and a viscosity adjusting agent, a pH adjusting agent, a perfume, a dye, and a hair conditioning agent are included.
- a pearlescent adjuvant such as ethylene glycol monostearate, and ethylene glycol distearate
- a preservative such as methyl ⁇ -Hydroxybenzoate and a mixture of methyl chloroisothiazolinone and methyl isothiazolinone
- a thickener and a viscosity adjusting agent such as sodium chloride, ammonium chloride, and propylene glycol
- a pH adjusting agent such as citric acid, phosphoric acid, sodium hydroxide, and potassium hydroxide
- a hair conditioning agents such as polyquaternium-10, polyquaternium-7, methylpolysiloxane, dimethicone copolyol, and hydrolyzed animal protein, and a dye such as water-soluble tar are used, and further, a perfume may be used.
- the present disclosure provides a food composition for preventing or improving hair loss and a food composition for promoting hair generation or hair growth comprising a CXCL1 protein; or a CXCL1 protein and minoxidil as an active ingredient.
- the food composition of the present disclosure may be a health functional food
- the “health functional food” means a food manufactured or processed by using raw materials or ingredients having useful functions to the human body in accordance with the Health Functional Food Act, No. 6727
- the “functionality” means intake for adjusting nutrients on a structure and a function of the human body or obtaining a useful effect for health such as a physiological action.
- the food composition may additionally include food additives, and suitability as the “food additives” is determined based on a scale and a standard for the corresponding item according to the general regulations and general test methods of the Food Additives Codex approved by the Korean Food and Drug Administration unless otherwise provided.
- Items disclosed in the “Food Additives Codex” may include, for example, chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid, natural additives such as persimmon extract, licorice extract, crystalline celluloses, and guar gums, and mixed agents such as a sodium L-glutamate agent, a noodles-added alkaline agent, a preservative agent, or a tar coloring agent.
- chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid
- natural additives such as persimmon extract, licorice extract, crystalline celluloses, and guar gums
- mixed agents such as a sodium L-glutamate agent, a noodles-added alkaline agent, a preservative agent, or a tar coloring agent.
- the foods including the active ingredient of the present disclosure may include confectionery such as bread, rice cake, nuts, candy, chocolate, chewing gum, and jam; ice cream products such as ice cream, frozen desserts, and ice cream powder; dairy products such as milk, low fat milk, lactase milk, processed milk, goat milk, fermented milk, butter milk, concentrated milk, milk cream, butter milk, natural cheese, processed cheese, milk powder, and milk serums; meat products such as meat products, egg products, and hamburgers; fish products such as fish processed products such as fish paste, ham, sausage, and bacon; noodles such as ramen noodles, dried noodles, fresh noodles, instant fried noodles, instant dried noodles, improved noodles, frozen noodles, and pastas; beverages such as fruit drinks, vegetable beverages, carbonated beverages, soybean milks, lactic beverages such as yogurt, and mixed drinks; seasonal foods such as soy sauce, miso, Kochujang, Chunjang, Chonggukjang, Mixed Jang, vinegar, sauces, tomato ketchup, curry, and dressing; margarine
- the composition of the present disclosure may additionally include various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salt thereof, alginic acid and salt thereof, organic acid, a protective colloidal thickener, a pH adjusting agent, a stabilizer, a preservative, glycerin, alcohol, a carbonic acid agent used in a carbonated drink, or the like in addition to the ingredients.
- the composition of the present disclosure may include pulps for preparing natural fruit juices, fruit juice beverages, and vegetable beverages.
- the ingredients may be used independently or in combination. Although the ratio of the additives does not matter, generally, the ratio is selected in a range of 0.01 to 0.1 part by weight per 100 parts by weight of the composition of the present disclosure.
- beverage composition including the active ingredient of the present disclosure
- various flavoring agents or natural carbohydrates, or the like may be included as an additional ingredient.
- natural carbohydrates include general sugars such as monosaccharides (for example, glucose, fructose, and the like); disaccharides (for example, maltose, sucrose, and the like); and polysaccharides (for example, dextrin, cyclodextrin, and the like), and sugar alcohols such as xylitol, sorbitol, and erythritol.
- flavoring agents other than the above examples, natural flavoring agents (thaumatin, stevia extract (for example, Rebaudioside A, Glycyrrhizin, and the like) and synthetic flavoring agents (saccharin, aspartame, and the like) may be advantageously used.
- natural flavoring agents thaumatin, stevia extract (for example, Rebaudioside A, Glycyrrhizin, and the like)
- synthetic flavoring agents sacharin, aspartame, and the like
- the present disclosure provides a complex formulation for preventing or treating hair loss comprising a CXCL1 (chemokine (C-X-C motif) ligand 1) protein and minoxidil.
- CXCL1 chemokine (C-X-C motif) ligand 1
- the complex formulation includes the CXCL1 (chemokine (C-X-C motif) ligand 1) protein and the minoxidil as an active ingredient, and the CXCL1 protein and the minoxidil may be included with a weight ratio of 1:1 to 1:20, respectively, preferably 1:1 to 1:15, and more preferably 1:1 to 1:10.
- a composition in which the CXCL1 protein and the minoxidil are mixed with 1 ⁇ g/ml and 10 ⁇ g/ml is provided.
- the complex formulation may generate new hair about three times greater than that of a PBS-administered group to exhibit an excellent effect of promoting hair generation.
- the effect is a significantly excellent effect as compared with the minoxidil-alone administration and a significantly excellent effect as compared with the CXCL1 protein-alone administration which generates new hair which is about two times greater than that of the PBS-administered group. It can be seen that the complex formulation exhibits a synergic effect of promoting hair generation and promoting hair growth.
- the present disclosure provides a method for preventing or treating hair loss comprising treating with a CXCL1 protein; or a CXCL1 protein and minoxidil to a subject.
- the present disclosure provides a method for improving hair loss comprising treating with a CXCL1 protein; or a CXCL1 protein and minoxidil to a subject.
- Another object of the present disclosure provides a method for promoting hair generation or hair growth comprising treating with a CXCL1 protein; or a CXCL1 protein and minoxidil to a subject.
- preventing used in this specification means all activities which suppress or delay hair loss by administering the composition of the present disclosure and the “improving” or “treating” means all activities which improve or beneficially change symptoms associated with hair loss by the composition of the present disclosure.
- subject used in this specification is a subject in which hair loss is in progress or may be in progress and a subject requiring an effect of hair generation and hair growth, and means a subject in which hair loss is delayed, suppressed, or improved or hair generation or hair growth may be promoted by treating with the CXCL1 protein; or the CXCL1 protein and the minoxidil of the present disclosure.
- the subject may be mammals including the human.
- treatment used in this specification may include all activities which administer and contact the CXCL1 protein; or the CXCL1 protein and the minoxidil to the subject without limitation.
- CXCL1 chemokine (C-X-C motif) ligand 1 (CXCL1) protein was purchased from Peprotech. A result of analyzing an amino acid sequence and a DNA base sequence of the obtained CXCL1 protein was illustrated in SEQ ID NO:1 and SEQ ID NO:2.
- Minoxidil was used by purchasing 2% (w/v) minoxidil which was sold under the trade name of Rogaine® from Jonhson & Johnson Healthcare Co., Ltd. in USA.
- DPC human dermal papilla cell proliferation test which is a representative in vitro cell test system for measuring hair proliferation was performed. 1 ng/ml or 5 ng/ml of the CXCL1 protein in Example 1 was treated to DPC, proliferation for 40 hrs was measured, and the result was illustrated in FIG. 1 .
- the CXCL1 protein had an excellent cell proliferation effect to be used for treating hair loss or promoting hair growth.
- CXCL1 human chemokine (C-X-C motif) ligand 1 (SEQ ID NO:1) protein was subcutaneously injected to the back once.
- PBS phosphate buffered saline
- BSA phosphate buffered saline
- the measured hair weight was 40 mg, whereas the group treated with the CXCL1 protein was 80 mg, and as a result, it was verified that in the case of the group treated with the CXCL1 protein, an effect of promoting the hair generation was excellent.
- a recombinant protein CXCL1 was mixed with 2% minoxidil (Women's Rogaine, Johnson & Johnson Healthcare Products, USA) to be 1 ⁇ g/ml and 10 ⁇ g/ml, respectively.
- the mixture of the minoxidil and the CXCL1 protein was applied to the back skin of the hair-removed mouse for 14 days by 100 ⁇ g/ml per day.
- a PBS-alone applied group and a 2% minoxidil-alone treated group were set.
- the hair generation in the back of the mouse was tracked and observed for 14 days and newly generated hair was obtained again and the weight was measured, and the result was illustrated in FIGS. 4 and 5 .
- the CXCL1 protein of the present disclosure has an effect of promoting hair generation at the time of administering alone and may induce a significantly excellent effect of promoting hair generation as compared with an effect of promoting hair generation of minoxidil at the time of administering with the minoxidil.
- CXCL1 protein or CXCL1 protein and minoxidil 20 mg Lactose 100 mg Talc 10 mg
- the ingredients were mixed and packed in an airtight bag to prepare the powder.
- CXCL1 protein or CXCL1 protein and minoxidil 10 mg Corn starch 100 mg Lactose 100 mg Magnesium stearate 2 mg
- the ingredients were mixed and tableted according to a general tablet preparing method to prepare the tablet.
- CXCL1 protein or CXCL1 protein and minoxidil 10 mg Crystalline cellulose 3 mg Lactose 14.8 mg Magnesium stearate 0.2 mg
- the ingredients were mixed and filled in a gelatin capsule according to a general capsule preparing method to prepare the capsule.
- CXCL1 protein or CXCL1 protein and minoxidil 10 mg Mannitol 180 mg Sterile distilled water for injection 2974 mg Na 2 HPO 4 2H 2 O 26 mg
- the injection was prepared with the content of ingredients per ampoule (2 ml) according to a general preparing method of the injection.
- CXCL1 protein or CXCL1 protein and minoxidil 20 mg Isomerized glucose 10 g Mannitol 5 g Purified water suitable amount
- liquid solution According to a general preparing method of the liquid solution, respective ingredients were added in purified water and dissolved, added with a suitable amount of lemon flavoring, and mixed and then added with purified water so as to be adjusted to the entire 100 ml, and then filled in a dark amber bottle and sterilized to prepare the liquid solution.
- CXCL1 protein; or CXCL1 protein and minoxidil 1.0 wt % Glycerin 4.0 wt % Vaseline 3.5 wt % Triethanolamine 2.1 wt % Liquid paraffin 53 wt % Squalane 3.0 wt % Wax 2.6 wt % Tocopheryl acetate 5.4 wt % Polysorbate 60 3.2 wt % Carboxyl vinyl polymer 1.0 wt % Sorbitan Sesquioleate 3.1 wt % Fragrance trace Antiseptic agent trace Purified water remaining amount
- CXCL1 protein; or CXCL1 protein and minoxidil 5.8 wt % Sodium lauryl sulfate 35 wt % Glycerin 1 wt % Lauramide DEA 3.5 wt % Propylene glycol 1 wt % Cocamidopropyl betaine 1 wt % Cetyl alcohol 0.1 wt % Glycol distearate 0.5 wt % Butylene glycol 8 wt % Methylparaben 0.2 wt % Triethanolamine 0.1 wt % Citric acid 0.1 wt % Polyquaternium-7 0.2 wt % Polyquaternium-10 0.12 wt % Olive oil fiji-7 ester 0.2 wt % Fragrance trace Antiseptic agent trace Purified water remaining amount
- CXCL1 protein; or CXCL1 protein and minoxidil 100 mg Vitamin mixture suitable amount Vitamin A acetate 70 g Vitamin E 1.0 mg Vitamin B1 0.13 mg Vitamin B2 0.15 mg Vitamin B6 0.5 mg Vitamin B12 0.2 g Vitamin C 10 mg Biotin 10 g Nicotinamide 1.7 mg Folic acid 50 g Calcium pantothenate 0.5 mg Mineral mixture suitable amount Ferrous sulfate 1.75 mg Zinc oxide 0.82 mg Magnesium carbonate 25.3 mg First potassium phosphate 15 mg Second potassium phosphate 55 mg Potassium citrate 90 mg Calcium carbonate 100 mg Magnesium chloride 24.8 mg
- a composition ratio of the mixture of vitamins and mineral was set by mixing ingredients relatively suitable for a health food, but a mixed ratio may be randomly modified. According to a general preparing method of the health food, the ingredients were mixed to prepare granules and may be used for preparing the health food composition according to a general method.
- CXCL1 protein or CXCL1 protein and minoxidil 100 mg Vitamin C 15 g Vitamin E (powder) 100 g Iron lactate 19.75 g Zinc oxide 3.5 g Nicotinamide 3.5 g Vitamin A 0.2 g Vitamin B1 0.25 g Vitamin B2 0.3 g Water required amount
- the ingredients were mixed, stirred and heated for about 1 hour at 85° C., a prepared solution was filtrated to be obtained in a sterilized container of 2 L, sterilized after sealing, and refrigerated, and then used for preparing the health beverage composition of the present disclosure.
- composition ratio was set by mixing ingredients relatively suitable for a favorite beverage, but a mixed ratio may be randomly modified and implemented according to regional and national preference such as demand layers, demand countries, and a purpose of use.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
CXCL1 protein; or CXCL1 protein and |
20 mg | ||
Lactose | 100 | ||
Talc | |||
10 mg | |||
CXCL1 protein; or CXCL1 protein and |
10 | ||
Corn starch | |||
100 | |||
Lactose | |||
100 | |||
Magnesium stearate | |||
2 mg | |||
CXCL1 protein; or CXCL1 protein and |
10 mg | ||
Crystalline cellulose | 3 mg | ||
Lactose | 14.8 mg | ||
Magnesium stearate | 0.2 mg | ||
CXCL1 protein; or CXCL1 protein and |
10 mg | ||
Mannitol | 180 mg | ||
Sterile distilled water for injection | 2974 mg | ||
Na2HPO42H2O | 26 mg | ||
CXCL1 protein; or CXCL1 protein and |
20 mg | ||
Isomerized glucose | 10 g | ||
Mannitol | 5 g | ||
Purified water suitable amount | |||
CXCL1 protein; or CXCL1 protein and minoxidil | 0.6 wt % | ||
Glycerin | 5.1 wt % | ||
Propylene glycol | 4.2 wt % | ||
Tocopheryl acetate | 3.0 wt % | ||
Liquid paraffin | 4.6 wt % | ||
Triethanolamine | 1.0 wt % | ||
Squalane | 3.1 wt % | ||
Macadamia nut oil | 2.5 | ||
Polysorbate | |||
60 | 1.6 wt % | ||
Sorbitan Sesquioleate | 1.6 wt % | ||
Propylparaben | 0.6 wt % | ||
Carboxyl vinyl polymer | 1.5 wt % | ||
Fragrance trace | |||
Antiseptic agent trace | |||
Purified water remaining amount | |||
CXCL1 protein; or CXCL1 protein and minoxidil | 1.0 wt % | ||
Glycerin | 4.0 wt % | ||
Vaseline | 3.5 wt % | ||
Triethanolamine | 2.1 wt % | ||
Liquid paraffin | 53 wt % | ||
Squalane | 3.0 wt % | ||
Wax | 2.6 wt % | ||
Tocopheryl acetate | 5.4 | ||
Polysorbate | |||
60 | 3.2 wt % | ||
Carboxyl vinyl polymer | 1.0 wt % | ||
Sorbitan Sesquioleate | 3.1 wt % | ||
Fragrance trace | |||
Antiseptic agent trace | |||
Purified water remaining amount | |||
CXCL1 protein; or CXCL1 protein and minoxidil | 5.8 wt % | ||
Sodium lauryl sulfate | 35 wt % | ||
Glycerin | 1 wt % | ||
Lauramide DEA | 3.5 wt % | ||
Propylene glycol | 1 wt % | ||
Cocamidopropyl betaine | 1 wt % | ||
Cetyl alcohol | 0.1 wt % | ||
Glycol distearate | 0.5 wt % | ||
Butylene glycol | 8 wt % | ||
Methylparaben | 0.2 wt % | ||
Triethanolamine | 0.1 wt % | ||
Citric acid | 0.1 wt % | ||
Polyquaternium-7 | 0.2 wt % | ||
Polyquaternium-10 | 0.12 wt % | ||
Olive oil fiji-7 ester | 0.2 wt % | ||
Fragrance trace | |||
Antiseptic agent trace | |||
Purified water remaining amount | |||
CXCL1 protein; or CXCL1 protein and |
100 | mg | ||
Vitamin mixture suitable amount | ||||
Vitamin A acetate | 70 | g | ||
Vitamin E | 1.0 | mg | ||
Vitamin B1 | 0.13 | mg | ||
Vitamin B2 | 0.15 | mg | ||
Vitamin B6 | 0.5 | mg | ||
Vitamin B12 | 0.2 | | ||
Vitamin C | ||||
10 | mg | |||
Biotin | 10 | g | ||
Nicotinamide | 1.7 | mg | ||
Folic acid | 50 | g | ||
Calcium pantothenate | 0.5 | mg | ||
Mineral mixture suitable amount | ||||
Ferrous sulfate | 1.75 | mg | ||
Zinc oxide | 0.82 | mg | ||
Magnesium carbonate | 25.3 | mg | ||
First potassium phosphate | 15 | mg | ||
Second potassium phosphate | 55 | mg | ||
Potassium citrate | 90 | | ||
Calcium carbonate | ||||
100 | mg | |||
Magnesium chloride | 24.8 | mg | ||
CXCL1 protein; or CXCL1 protein and |
100 | mg | ||
Vitamin C | 15 | g | ||
Vitamin E (powder) | 100 | g | ||
Iron lactate | 19.75 | g | ||
Zinc oxide | 3.5 | g | ||
Nicotinamide | 3.5 | g | ||
Vitamin A | 0.2 | g | ||
Vitamin B1 | 0.25 | g | ||
Vitamin B2 | 0.3 | g | ||
Water required amount | ||||
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/014,812 US10512670B2 (en) | 2016-08-08 | 2018-06-21 | Pharmaceutical composition for preventing or treating hair loss comprising chemokine (C-X-C motif) ligand 1 (CXCL1) protein or CXCL1 protein and minoxidil as active ingredient |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160100966A KR101657082B1 (en) | 2016-08-08 | 2016-08-08 | Pharmaceutical composition for preventing or treating hair loss comprising CXCL1 protein |
KR10-2016-0100966 | 2016-08-08 | ||
PCT/KR2016/014234 WO2018030590A1 (en) | 2016-08-08 | 2016-12-06 | Composition for preventing or treating hair loss including chemokine (c-x-c motif) ligand 1 (cxcl1) protein as active ingredient |
US16/014,812 US10512670B2 (en) | 2016-08-08 | 2018-06-21 | Pharmaceutical composition for preventing or treating hair loss comprising chemokine (C-X-C motif) ligand 1 (CXCL1) protein or CXCL1 protein and minoxidil as active ingredient |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2016/014234 Continuation-In-Part WO2018030590A1 (en) | 2016-08-08 | 2016-12-06 | Composition for preventing or treating hair loss including chemokine (c-x-c motif) ligand 1 (cxcl1) protein as active ingredient |
US15/317,895 Continuation-In-Part US20190151219A1 (en) | 2016-08-08 | 2016-12-06 | Composition for preventing or treating hair loss comprising chemokine (c-x-c motif) ligand 1 (cxcl1) protein |
Publications (2)
Publication Number | Publication Date |
---|---|
US20180289772A1 US20180289772A1 (en) | 2018-10-11 |
US10512670B2 true US10512670B2 (en) | 2019-12-24 |
Family
ID=63710609
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/014,812 Active US10512670B2 (en) | 2016-08-08 | 2018-06-21 | Pharmaceutical composition for preventing or treating hair loss comprising chemokine (C-X-C motif) ligand 1 (CXCL1) protein or CXCL1 protein and minoxidil as active ingredient |
Country Status (1)
Country | Link |
---|---|
US (1) | US10512670B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021232054A1 (en) * | 2020-05-12 | 2021-11-18 | Chemistryrx | Compositions for treating hair loss |
CN115475168B (en) * | 2022-10-18 | 2024-02-13 | 湖北工业大学 | Minoxidil-containing pharmaceutical composition and preparation method and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080287349A1 (en) | 2003-05-09 | 2008-11-20 | Jeffrey Peterson | Fibroblast growth factor 20 and methods of use thereof |
KR20100032099A (en) | 2008-09-17 | 2010-03-25 | 주식회사 에스티씨라이프 | Cosmetic composition comprising stem cells-conditioned media |
WO2012061537A2 (en) | 2010-11-02 | 2012-05-10 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
US20150290104A1 (en) | 2011-01-31 | 2015-10-15 | Allergan, Inc. | Method of enhancing hair growth |
-
2018
- 2018-06-21 US US16/014,812 patent/US10512670B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080287349A1 (en) | 2003-05-09 | 2008-11-20 | Jeffrey Peterson | Fibroblast growth factor 20 and methods of use thereof |
KR20100032099A (en) | 2008-09-17 | 2010-03-25 | 주식회사 에스티씨라이프 | Cosmetic composition comprising stem cells-conditioned media |
WO2012061537A2 (en) | 2010-11-02 | 2012-05-10 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
US20150290104A1 (en) | 2011-01-31 | 2015-10-15 | Allergan, Inc. | Method of enhancing hair growth |
Non-Patent Citations (6)
Also Published As
Publication number | Publication date |
---|---|
US20180289772A1 (en) | 2018-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3281635B1 (en) | Pharmaceutical composition for preventing or treating hair loss comprising chemokine (c-x-c motif) ligand 1 (cxcl1) protein or cxcl1 protein and minoxidil as active ingredient | |
US10975130B2 (en) | Composition for preventing hair loss or promoting hair growth | |
US10512670B2 (en) | Pharmaceutical composition for preventing or treating hair loss comprising chemokine (C-X-C motif) ligand 1 (CXCL1) protein or CXCL1 protein and minoxidil as active ingredient | |
US20190216707A1 (en) | Composition for preventing hair loss and promoting hair growth, comprising phytoestrogen as an active ingredient | |
RU2709195C1 (en) | Pharmaceutical composition for preventing or treating hair loss, comprising protein of chemokine ligand 1, containing c-x-c motif (cxcl1), and minoxidil as active ingredients | |
JP5819209B2 (en) | Differentiation promoter from stem cells to brown adipocytes | |
AU2016255815B2 (en) | Oral care composition | |
JP6823889B2 (en) | Composition for anti-aging or skin regeneration containing piperonyl acid as an active ingredient | |
KR101671361B1 (en) | Pharmaceutical composition for preventing or treating hair loss comprising TYMP(thymidine phosphorylase) protein | |
JP6956846B1 (en) | Low back pain improver and trunk muscle strength improver | |
US20230144955A1 (en) | Peptide for preventing or treating hair loss, and use thereof | |
KR101701217B1 (en) | Pharmaceutical composition containing material extracted from chestnut burr for preventing or treating alopecia | |
EP3127547B1 (en) | Composition comprising extract of alpine wormwood | |
RU2794988C1 (en) | Composition for stimulating hair growth and preventing hair loss | |
KR20210037186A (en) | A pharmaceutical composition for the prevention and treatment of alopecia comprising boehmite as a effective ingredient | |
EP3165230A1 (en) | Composition containing masterwort extract | |
KR102386651B1 (en) | Composition for preventing or treating hair loss comprising tiplaxtinin | |
WO2021118323A1 (en) | Tandem insulin-like growth factor-1 and composition comprising same as active ingredient for preventing hair loss or promoting hair regrowth | |
KR20230065584A (en) | Composition for improving skin elasticity during wound healing regeneration comprising RGD-containing Elastin-Like Polypeptide and stem cell | |
JP2018150269A (en) | αMSH(1-8) EXPRESSION INHIBITORS | |
KR20230103027A (en) | Composition for prevention of hair loss or improvement of hair growth | |
KR101617770B1 (en) | Composition comprising T.s 15-1 protein from Intestinal Parasitic Nematode for anti-aging of skin or wound healing | |
KR20230140008A (en) | Composition for preventing hair loss, promoting hair growth or improving scalp condition comprising pinitol as an active ingredient | |
KR20160071523A (en) | A composition for preventing hair loss and stimulating hair growth comprising Poncirus trifoliate extract | |
KR20230169700A (en) | Composition for preventing, improving or treating hair loss symptoms, including TRAIL, and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SCM LIFESCIENCE CO., LTD., KOREA, REPUBLIC OF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SONG, SUN UK;SUNG, JONG HYUK;REEL/FRAME:047436/0734 Effective date: 20180319 |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: AWAITING TC RESP, ISSUE FEE PAYMENT VERIFIED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 4 |